ClinicalTrials.gg
RecruitingNCT07551427Updated Jul 15, 2026

A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis

A Phase 2 interventional study of TQ05105 Tablets (Rovadicitinib Tablets) in Myelofibrosis, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 24 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited — 3 open to participants now, 5 under way, none of them phase 3. Primary Myelofibrosis · Sino Biopharmaceutical Limited.

Planned enrollment
3rd of 10
51 · median 28
Started
2026
with 3 others
Phase 2
Only one
of the 10
Registered
8th of 10
by date

Among the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2026, is the only one in phase 2, and was the 8th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is an open-label, single-arm, multi-center phase II study consisting of two cohorts. Cohort 1 evaluates the pharmacokinetics (PK) of TQ05105 in myelofibrosis participants with normal, mild, or moderate renal impairment to guide dosing. Cohort 2 evaluates the efficacy and safety of TQ05105 in participants with intermediate/high-risk myelofibrosis who are refractory, relapsed, or intolerant to prior Janus kinase (JAK) inhibitor therapy.

03

Conditions studied

  • Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary and signed , good compliance.
  2. Age ≥18 years (at time of signing informed consent); performance status (ECOG PS) 0-2; ≥24 weeks.
  3. Diagnosis of primary myelofibrosis (PMF) per World Health Organization (WHO) 2016, or post-polycythemia vera myelofibrosis (post-PV-MF) or post-essential thrombocythemia myelofibrosis (post-ET-MF) per International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria; Janus kinase 2 (JAK2) mutation status not restricted.
  4. Intermediate or high risk per Dynamic International Prognostic Scoring System (DIPSS).
  5. Cohort 1: Renal function classified as normal, mild impairment, or moderate impairment. Cohort 2: Prior Janus kinase (JAK) inhibitor therapy with , relapsed, or intolerant.
  6. Spleen enlargement (except Cohort 1).
  7. Peripheral blood and bone marrow blasts ≤10%.
  8. No growth factors, colony-stimulating factors, thrombopoietin, or transfusion within 2 weeks before first dose; and routine blood parameters meet requirements within 7 days before first dose.
  9. Adequate major organ function within 7 days before first dose per protocol (renal function not restricted for Cohort 1).
  10. Agreement to use effective during the study and for 6 months after; negative pregnancy test for females of ; non-lactating.

Exclusion criteria

Exclusion Criteria:

  1. Prior stem cell transplantation, or autologous stem cell transplantation within 3 months before first dose, or planned stem cell transplantation.
  2. Prior treatment with 2 or more Janus kinase (JAK) inhibitors (except Cohort 1).
  3. Prior splenectomy or splenic radiotherapy within 6 months before first dose.
  4. Other within 3 years before first dose or currently present (exceptions per protocol).
  5. Factors affecting oral drug absorption.
  6. Non-hematologic toxicity from prior therapy not recovered to ≤ grade 1 (excluding hypertension and alopecia).
  7. Major surgery or significant traumatic injury within 4 weeks before first dose.
  8. Congenital bleeding or coagulation disorders.
  9. Arterial/venous thrombosis event within 6 months before first dose.
  10. History of substance abuse or mental disorder.
  11. Active or uncontrolled severe infection.
  12. Active virus (HBV) or virus (HCV) infection.
  13. Grade ≥2 myocardial ischemia or infarction, arrhythmia, , or grade ≥2 congestive heart failure.
  14. Uncontrolled hypertension despite standard therapy.
  15. Renal failure requiring hemodialysis or peritoneal dialysis.
  16. Newly diagnosed pulmonary interstitial fibrosis or drug-related interstitial lung disease within 3 months before first dose.
  17. History of immunodeficiency or organ transplantation.
  18. Epilepsy requiring treatment.
  19. Use of protocol-prohibited myelofibrosis (MF) medications, immunomodulators, or within specified time before first dose.
  20. Use of Chinese patent medicines with anti-tumor indications approved by National Medical Products Administration (NMPA) within 2 weeks before first dose.
  21. Uncontrolled pleural effusion, pericardial effusion, or ascites.
  22. within 4 weeks before first dose or planned during the study.
  23. Known to study drug or .
  24. Diagnosis of active disease within 2 years before first dose.
  25. Participation in another interventional clinical trial with drug within 4 weeks before first dose.
  26. Any condition that, in the investigator's judgment, seriously endangers subject safety or interferes with study completion.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (estimated)

Study arms

  • Experimental
    TQ05105 Tablets

    TQ05105 Tablets, 28 days as a treatment cycle.

    Drug: TQ05105 Tablets (Rovadicitinib Tablets)

Interventions

  • TQ05105 is an inhibitor of Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Rho-associated coiled-coil containing protein kinase 1 (ROCK1) and 2 (ROCK2).

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with ≥35% reduction in spleen volume from baseline at week 24 (SVR35)

    SVR35 at week 24 as assessed by Independent Review Committee (IRC)

    Time frame: up to 24 weeks

  2. Peak concentration (Cmax)

    Maximum plasma concentration of TQ05105 and its metabolite(s).

    Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)

  3. Time to peak concentration (Tmax)

    Time to reach maximum plasma concentration of TQ05105 and its metabolite(s).

    Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)

  4. Elimination half-life (t1/2)

    Half-life of TQ05105 and its metabolite(s) in plasma.

    Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)

  5. Area under the curve from time 0 to last measurable concentration (AUC0-t)

    AUC from time 0 to the last measurable concentration of TQ05105 and its metabolite(s).

    Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)

  6. Area under the curve from time 0 to infinity (AUC0-∞)

    AUC from time 0 extrapolated to infinity for TQ05105 and its metabolite(s).

    Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)

  7. Total clearance (CLt)

    Total body clearance of TQ05105 and its metabolite(s) from plasma.

    Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)

  8. Renal clearance (CLr)

    Renal clearance of TQ05105 and its metabolite(s).

    Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)

  9. Apparent volume of distribution (Vd/F)

    Apparent volume of distribution of TQ05105 and its metabolite(s) after oral administration.

    Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)

  10. Elimination rate constant (λz)

    Terminal elimination rate constant of TQ05105 and its metabolite(s).

    Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)

Secondary outcomes

  1. Best response rate of spleen volume reduction

    Proportion of subjects with at least one occurrence of ≥35% reduction in spleen volume from baseline.

    Time frame: up to 48 weeks

  2. Onset time of splenic response

    The time interval from the first administration to the date when the spleen volume was reduced by ≥ 35 % from the baseline.

    Time frame: up to 48 weeks

  3. Duration of maintenance of at least 35% Reduction in Spleen Volume (DoMSR)

    Duration of spleen volume reduction ≥ 35% from baseline: the time between the date when the spleen volume reduction ≥ 35% from baseline occurs for the first time and the date when the spleen volume reduction \< 35% from baseline.

    Time frame: up to 48 weeks

  4. Percentage change in spleen volume from baseline at planned visits

    Percentage change in spleen volume relative to baseline at each planned visit.

    Time frame: up to 48 weeks

  5. SVR35 at each planned visit time point

    Proportion of subjects with ≥35% reduction in spleen volume from baseline at each planned visit.

    Time frame: up to 48 weeks

  6. The proportion of subjects whose total symptom score of Myeloproliferative neoplasm- Symptom Assessment Form- Total Symptom Score (MPN-SAF TSS) decreased by more than 50% compared with baseline.

    The proportion of subjects whose total symptom score of MPN-SAF TSS decreased by more than 50% compared with baseline. Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF-TSS) is an effective tool for evaluating the disease burden of patients with myeloproliferative neoplasms. The higher the score, the more severe the symptoms. Each symptom is scored according to the severity, from asymptomatic (0 points) to the most serious (10 points), a total of 10 levels,The sum of the symptom scores is the MPN-SAF-TSS score.

    Time frame: up to 48 weeks

  7. Percentage change in MPN-SAF TSS from baseline at planned visits

    Percentage change in MPN-SAF TSS from baseline at planned visits.

    Time frame: up to 48 weeks

  8. Proportion of subjects with at least one occurrence of ≥50% reduction in MPN-SAF TSS from baseline

    Proportion of subjects with at least one occurrence of ≥50% reduction in MPN-SAF TSS from baseline.

    Time frame: up to 48 weeks

  9. Time to first ≥50% reduction in MPN-SAF TSS from baseline

    Time from first dose to first documentation of ≥50% reduction in MPN-SAF TSS from baseline.

    Time frame: up to 48 weeks

  10. Duration of ≥50% reduction in MPN-SAF TSS from baseline

    Time from first achievement of ≥50% reduction in MPN-SAF TSS to loss of this response.

    Time frame: up to 48 weeks

  11. Objective response rate (ORR)

    Proportion of subjects achieving complete remission (CR) or partial remission (PR).

    Time frame: up to 48 weeks

  12. Progression-free survival (PFS)

    The time interval from the first medication to the date of the occurrence of any of the following events, whichever occurs first, shall prevail :(1) Spleen volume increased by≥25% compared with the screening period ; (2) Death caused by any cause.

    Time frame: From first dose to event (up to study completion) , an average of 3 years

  13. Leukemia free survival (LFS)

    Time from first dose to leukemic transformation or death.

    Time frame: From first dose to event (up to study completion) , an average of 3 years

  14. Overall Survival (OS)

    OS is defined as the time from the first time the subject received treatment to death due to any cause

    Time frame: From first dose to event (up to study completion) , an average of 3 years

  15. Incidence of adverse events (AEs)

    Incidence of adverse events determined and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0.

    Time frame: From baseline up to 4 weeks after last dose

  16. Severity of AEs

    All adverse medical events that occur after the subject receives the investigational drug may be manifested as symptoms, signs, disease, or laboratory abnormalities, but are not necessarily causally related to the investigational drug, evaluated according to the CTCAE v6.0.

    Time frame: From baseline up to 4 weeks after last dose

  17. Urinary excretion amount (Ae0-24)

    Amount of drug excreted in urine within 24 hours after single and multiple oral doses of TQ05105.

    Time frame: Pre-dose (-24-0 hours), 0-3, 3-6, 6-9, 9-12, 12-24 hours post-dose

  18. Cumulative urinary excretion rate (Ae0-24%)

    Percentage of the dose excreted in urine within 24 hours after single and multiple oral doses of TQ05105.

    Time frame: Pre-dose (-24-0 hours), 0-3, 3-6, 6-9, 9-12, 12-24 hours post-dose

  19. Proportion of subjects receiving red blood cell transfusion within 24 weeks

    Proportion of subjects who receive red blood cell transfusion during the first 24 weeks of treatment.

    Time frame: Up to 24 weeks

  20. Proportion of subjects receiving platelet transfusion within 24 weeks

    Proportion of subjects who receive platelet transfusion during the first 24 weeks of treatment.

    Time frame: Up to 24 weeks

07

Study locations

24 of 24 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Apr 24, 2026
StartActual
Jun 18, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2029
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07551427
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
Jun 18, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Jul 15, 2026

Study contacts

Chunkang Chang, Doctor
Contact
changchunkang7010@aliyun.com
13764643870

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JAK2 Inhibitor TQ05105

Start the discussion